Giant Cell Tumor of Bone With Cartilage Matrix: A Clinicopathologic Study of 17 Cases.
Journal
The American journal of surgical pathology
ISSN: 1532-0979
Titre abrégé: Am J Surg Pathol
Pays: United States
ID NLM: 7707904
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
entrez:
16
5
2020
pubmed:
16
5
2020
medline:
21
10
2020
Statut:
ppublish
Résumé
Giant cell tumor of bone (GCT) is a benign locally aggressive neoplasm composed of mononuclear cells admixed with innumerable osteoclast-type giant cells. H3F3A gene mutations producing mutant histone protein product H3.3 have been identified in 96% of GCT; mutant H3.3 is reliably demonstrated by immunohistochemistry. GCT may contain woven bone and rarely, neoplastic cartilage nodules which causes diagnostic challenges with aggressive neoplasms such as osteosarcoma. We describe the features of GCT with cartilage matrix and report the next-generation sequencing findings in a subset of tumors. Seventeen cases of GCT with cartilage matrix form the cohort: 7 males and 10 females, 13 to 55 (mean: 25) years old. Tumors involved the fibula (6), femur (6), and patella, tibia, humerus, S1, and scapula (1 case each). Tumors were radiolucent, circumscribed, lytic, and expansile. All contained classic GCT, foci of cartilage matrix, and trabeculae of woven bone. Immunohistochemistry showed diffuse staining for H3.3 in 9/9 cases and 1 case was positive for S100 and SOX9 in the cartilage areas. Next-generation sequencing showed a mutation in the H3F3A gene in 6/6 cases. On follow-up, 2 patients who underwent resection showed no disease after 12, and 7 months, respectively. Three patients had recurrences 10, 12, and 27 months after curettage; there were no metastases. GCT with cartilage matrix is uncommon. The cartilage matrix is associated with woven bone suggesting the neoplastic cells may differentiate into chondrocyte-like and osteoblast-like cells. Recognition of this neoplasm is important to prevent misdiagnosis and overtreatment of affected patients.
Identifiants
pubmed: 32412716
doi: 10.1097/PAS.0000000000001446
pii: 00000478-202006000-00004
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
748-756Références
Athanasou NA, Bansal M, Forsyth R, et alFletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, et al. Giant cell tumour of bone. WHO Classification of Tumours of Soft Tissue and Bone, 4th edition. Lyon, France: International Agency for Research on Cancer; 2013:321–324.
Dickson BC, Li SQ, Wunder JS, et al. Giant cell tumor of bon express p63. Mod Pathol. 2008;21:369–375.
Maues De Paula A, Vasiljevic A, Giorgi R, et al. A diagnosis of giant cell-rich tumour of bone is supported by p63 immunohistochemistry, when more than 50% of cells is stained. Virchows Arch. 2014;465:487–494.
Yamamoto H, Iwasaki T, Yamada Y, et al. Diagnostic utility of histone H3.3 G34 W, G34R, and G34 V mutant-specific antibodies for giant cell tumors of bone. Hum Pathol. 2018;73:41–50.
Amary F, Berisha F, Ye H, et al. H3F3A (Histone 3.3) G34W immunohistochemistry: a reliable marker defining benign and malignant giant cell tumor of bone. Am J Surg Pathol. 2017;41:1059–1068.
Schaefer IM, Fletcher JA, Nielsen GP, et al. Immunohistochemistry for histone H3G34W and H3K36M is highly specific for giant cell tumor of bone and chondroblastoma, respectively, in FNA and core needle biopsy. Cancer Cytopathol. 2018;126:552–566.
Alberghini M, Kliskey K, Krenacs T, et al. Morphological and immunophenotypic features of primary and metastatic giant cell tumour of bone. Virchows Arch. 2010;456:97–103.
Lüke J, von Baer A, Schreiber J, et al. H3F3A mutation in giant cell tumour of the bone is detected by immunohistochemistry using a monoclonal antibody against the G34W mutated site of the histone H3.3 variant. Histopathology. 2017;71:125–133.
Orosz Z, Athanasou NA. Giant cell-containing tumors of the bone. Surg Pathol Clin. 2017;10:553–573.
Behjati S, Tarpey PS, Presneau N, et al. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet. 2013;45:1479–1482.
Presneau N, Baumhoer D, Behjati S, et al. Diagnostic value of H3F3A mutations in giant cell tumour of bone compared to osteoclast-rich mimics. J Pathol Clin Res. 2015;1:113–123.
Cleven AHG, Höcker S, Briaire-de Bruijn I, et al. Mutation analysis of H3F3A and H3F3B as a diagnostic tool for giant cell tumor of bone and chondroblastoma. Am J Surg Pathol. 2015;39:1576–1583.
Nohr E, Lee LH, Cates JM, et al. Diagnostic value of histone 3 mutations in osteoclast-rich bone tumors. Hum Pathol. 2017;68:119–127.
Righi A, Mancini I, Gambarotti M, et al. Histone 3.3 mutations in giant cell tumor and giant cell–rich sarcomas of bone. Hum Pathol. 2017;68:128–135.
Kervarrec T, Collin C, Larousserie F, et al. H3F3 mutation status of giant cell tumors of the bone, chondroblastomas and their mimics: a combined high resolution melting and pyrosequencing approach. Mod Pathol. 2017;30:393–406.
Wülling M, Delling G, Kaiser E. The origin of the neoplastic stromal cell in giant cell tumor of bone. Hum Pathol. 2003;34:983–993.
Huang L, Teng XY, Cheng YY, et al. Expression of preosteoblast markers and Cbfa-1 and Osterix gene transcripts in stromal tumour cells of giant cell tumour of bone. Bone. 2004;34:393–401.
Murata A, Fujita T, Kawahara N, et al. Osteoblast lineage properties in giant cell tumors of bone. J Orthop Sci. 2005;10:581–588.
Do I, Ryu KN, Han CS, et al. Giant cell tumor with an unusual cartilage matrix. Korean J Pathol. 2005;39:269–272.
Al-Ibraheemi A, Inwards CY, Zreik RT, et al. Histologic spectrum of giant cell tumor (GCT) of bone in patients 18 years of age and below: a study of 63 patients. Am J Surg Pathol. 2016;40:1702–1712.
Amary MF, Bacsi K, Maggiani F, et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol. 2011;224:334–343.
Bertoni F, Unni KK, Lucas DR, et al. Osteoblastoma with cartilaginous matrix. An unusual morphologic presentation in 18 cases. Am J Surg Pathol. 1993;17:69–74.
Della Rocca C, Huvos AG. Osteoblastoma: varied histological presentations with a benign clinical course. An analysis of 55 cases. Am J Surg Pathol. 1996;20:841–850.